Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
Milwaukee and Toronto (ots/PRNewswire) - Cedara, a Merge Healthcare company (Nasdaq: MRGE), and a leading independent developer of medical software technologies for the global healthcare market, and their Distributor in the Benelux, ImaXperts BV, have finalized the installation of a new FUSION PACS(TM) for the ...
Madrid (ots/PRNewswire) - Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used ...
Lugano, Switzerland and Lisboa, Portugal (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the signing of an agreement granting ANGELINI the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in PORTUGAL. ALOXI® is a strong and long acting ...
Madrid, Spain (ots/PRNewswire) - Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international institutional investors. The capital increase is expected to raise approximately one hundred (100) million euros. A "green shoe" of up to 15% of the amount raised can be exercised by ...
Copenhagen, Denmark (ots/PRNewswire) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE (European Society of Human Reproduction and Embryology) congress supports the efficacy of MENOPUR (menotrophin), a highly purified, naturally-derived infertility treatment belonging to the class of drugs known as gonadotrophins, ...
Barcelona, Spain (ots/PRNewswire) - The addition of Avastin(R) (bevacizumab, rhuMAb-VEGF) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal ...
Sao Paulo, Brazil (ots/PRNewswire) - - Miguel Nicolelis -- World-renowned Brazilian Neuroscientist -- to Perform the First Operation on a Human That Will Allow the Brain to Control Robotic Arms The Teaching and Research Institute of the Syrian-Lebanese Hospital in Sao Paulo (Instituto de Ensino e Pesquisa do Hospital Sirio-Libanes) announced today a ...
Seattle (ots/PRNewswire) - - Data on Microbiology of an Investigational Inhaled Antibiotic for Cystic Fibrosis to Be Presented in Crete Dr. Jane L. Burns will present Corus Pharma's Aztreonam Lysinate for Inhalation (AI) clinical Phase 2 microbiology results at the European Cystic Fibrosis Society Conference (ECFS) in Crete on Friday, June 24, 2005 at ...
Espoo, Finland (ots/PRNewswire) - Negotiations have been completed with the personnel representatives in Orion Diagnostica Oy, a subsidiary of Orion Corporation, concerning operational rearrangements at Orion Diagnostica's sites in Finland. As a result of the negotiations, a decision has been made to transfer the production operations of the Oulunsalo plant to Turku. There are 30 employees at the Oulunsalo site. ...
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the U.S. for Protection Against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...
Vienna, Austria (ots/PRNewswire) - - Data from ADEPT study showed HUMIRA slowed progression of structural joint damage Results from Abbott's Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) show that HUMIRA(R) (adalimumab) treated both joint and skin aspects of the disease and improved the quality of life measurements in patients with moderate ...
Cordis Medizinische Apparate GmbH
Miami (ots/PRNewswire) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the CYPHER(R) and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well as several other catheter-based products. Cordis intends to file an appeal with the ...
Stockholm, Sweden (ots/PRNewswire) - Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, announced that new data from a randomised, double-blind Phase 3 study demonstrate that Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg once every three weeks is at least as effective as ...
Research Triangle Park, North Carolina (ots/PRNewswire) - Quintiles Transnational Corp. today announced that Quintiles Laboratories Asia (QLAB Asia) has amended its existing agreement with Peking Union Medical College Hospital (PUMCH) to enhance central laboratory services in China. The new amended agreement with PUMCH enhances services for customers by allowing Quintiles central laboratory (QLAB) facilities in ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The study, involving 17 healthy subjects with mild to moderate plaque psoriasis, was designed to characterize the local efficacy and safety of three concentrations of CTA018. Results ...
San Diego, California (ots/PRNewswire) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has entered into an exclusive global license and co-development agreement with Novartis to develop, ...
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
Biasca, Switzerland (ots) - Helsinn Chemicals SA and Helsinn Advanced Synthesis SA have successfully passed a re-certification audit of its ISO14001 Environmental Management System. The audit by SGS took place on May 2nd and 3rd 2005. In parallel, Helsinn has also applied for an audit from SGS to inspect the Helsinn sites in relation to the Occupational Health and Safety Assessment Series (OHSAS) 18001 ...
Amsterdam, Netherlands (ots/PRNewswire) - - XML Content Management System at Heart of New User-Centric Solution That Brings Consistency to Technical Documents Across 100s of Medical Products Astoria Software, the leading provider of XML content management solutions, today announced that Siemens Medical ...
Cranberry Township, Pennsylvania (ots/PRNewswire) - Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal ...
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
Los Angeles (ots/PRNewswire) - Infotrieve, Inc. announced today the immediate availability of the company's Life Science Research Center(TM) (LSRC), a web-based information research tool that provides scientists with one-stop search access to critical information that impacts scientific workflow. The LSRC was designed to simplify research by eliminating the need for logins to multiple information sources including ...
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show ...
Orlando, Florida (ots/PRNewswire) - - New Results Presented at ASCO Results from five clinical studies of YONDELIS (TM) (trabectedin) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Florida, from 13-17 May 2005. YONDELIS is being developed by PharmaMar ...